미국 · 보도자료 · Arbutus Biopharma Corporation · 2026-09-30 11:30
2억 3,000만 달러 규모 공개매수 예비 결과 발표
WARMINSTER, Pa., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced the preliminary results of its tender offer (the “Offer”) to purchase for cancellation up to US$230 million in value of its common shares (the “Shares”). The Offer proceeded by way of
Arbutus Biopharma Corporation 다른 공시·급등 이유 보기 · GK의 공시레이더 — 미국·한국 실시간 공시
